Herceptin increases the effectiveness of chemotherapy by 1.5 times

On April 18, at the European Breast Cancer Conference held in Berlin, the results of a study were announced, according to which the administration of the drug Herceptin /Herceptin (trastuzumab) in combination with standard chemotherapy before surgery for breast cancer (neoadjuvant therapy) leads to complete eradication of the tumor in 45.5% of women, whereas those who received only chemotherapy had 30%. These important results of the GeparQuattro study indicate the effectiveness of early administration of Herceptin in HER2-positive breast cancer.

The results of GeparQuattro echo the data of other studies of neoadjuvant therapy with Herceptin – NOAH (NeOAdjuvant Herceptin) and TECHNO (Taxol-Epirubicin-Cyclophosphamid-Herceptin Neoadjuvant).

HER2-positive breast cancer is diagnosed in approximately 20-30% of cases of this disease. Usually, a tumor of this type progresses rapidly and recurs with a high degree of probability. Chemotherapy before surgery is prescribed in order to reduce a large (over 2 cm in diameter) tumor in order to improve the results of surgical treatment.

"Weekly PHARMACY" based on Roche materials

Portal "Eternal youth" www.vechnayamolodost.ru22.04.2008